Reports Q1 revenue $497,000, consensus $760,000. “We are pleased to have exceeded our enrollment target of 110 patients in our randomized study of 3 mg/kg of aplitabart plus FOLFIRI and bevacizumab in second line colorectal cancer,” said Fred Schwarzer, Chief Executive Officer of IGM Biosciences. “While we are still scheduling first doses for a few patients, we expect that final enrollment in this clinical trial will exceed 120 patients. We are also pleased that we have completed enrollment in the first dose cohort of our clinical trial of imvotamab in severe rheumatoid arthritis.”
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on IGMS:
- IGM Biosciences Announces First Quarter 2024 Financial Results and Provides Corporate Update
- IGM Biosciences weakness creates ‘interesting opportunity,’ says Stifel
- IGM Biosciences announces refocusing of Sanofi collaboration
- IGM Biosciences Announces Refocusing of Sanofi Collaboration
- IGM Biosciences to Present at the Stifel 2024 Virtual Targeted Oncology Forum